Table 4 Descriptive analysis of baseline clinical and therapeutical variables : monoinfected vs coinfected patients with HCV genotype 3.
Variables | HIV- (n = 181) | HIV+ (n = 72) | Odds Ratio (95% IC) | p-value |
|---|---|---|---|---|
Cirrhosis, % (n) | 66% (12) | 30.6% (22) | 6.1 (2.8-13.6) | <0.0001 |
HCV-RNA >500.000 IU/ml, % (n) | 46.9% (84) | 31.9% (23) | 0.53 (0.3-0.9) | 0.03 |
PegIFN alfa-2b, % (n) | 23.2% (42) | 29.2% (21) | 1.36 (0.7-2.5) | 0.32 |
PegIFN reduction, % (n) | 11.6% (21) | 5.6% (4) | 0.45 (0.13-1.3) | 0.15 |
Stop PegIFN % (n) | 16.6% (30) | 31.9% (23) | 2.35 (1.24-4.44) | 0.007 |
RBV reduction, % (n) | 12.2% (22) | 13.9% (10) | 1.6 (0.5-2.6) | 0.71 |
Stop RBV, % (n) | 9.4% (17) | 29.2% (21) | 3.95 (1.93-8.17) | <0.0001 |
Male gender, % (n) | 76.8% (139) | 81.9% (59) | 1.37 (0.7-2.8) | 0.37 |
Age >45 years, % (n) | 27.6% (50) | 48.6% (35) | 2.4 (1.4-4.4) | 0.001 |
PLT <130,000 cell/mm3, % (n) | 8.3% (15) | 33.3% (24) | 5.4 (2.7-11.5) | <0.0001 |
Variables | HIV- (n = 181) | HIV+ (n = 72) | Â | p -value |
ALT, mean (DS) | 139.7 (118.6) | 117.6 (75.5) | Â | 0.26 |
AST, mean (DS) | 78.7 (70.6) | 76.5 (49.9) | Â | 0.69 |
BMI, mean (DS) | 25.1 (3.7) | 23.6 (3.2) | Â | 0.006 |
Cholesterol, mean (DS) | 152.5 (39.3) | 148.9 (40) | Â | 0.52 |
Triglycerids, mean (DS) | 82.3 (45) | 108.5 (61.8) | Â | 0.0004 |
Glycemia, mean (DS) | 93.6 (21.9) | 90.2 (12.1) | Â | 0.39 |
Hb, mean (DS) | 15.3 (1.5) | 14.5 (2.1) | Â | 0.003 |
PT, mean (DS) | 102 (11.6) | 101 (12.6) | Â | 0.96 |
Neutrophils, mean (DS) | 3597 (1327) | 3118 (1364) | Â | 0.004 |
Weeks of treatment, mean (DS) | 20.7 (9.1) | 40.7 (17.8) | Â | <0.0001 |
Bilirubine, mean (DS) | 0.82 (0.45) | 1.55 (1.48) | Â | 0.0002 |
Albumine, mean (DS) | 4.63 (3.13) | 4.39 (0.47) | Â | 0.47 |
SVR rate, ITT analysis | HIV- (n = 181) | HIV+ (n = 72) | Odds Ratio (95% IC) | p -value |
SVR, % (n) | 76.8 % (139) | 68.1 % (72) | 0.65 (0.3-1.2) | 1.15 |
SVR rate, PP analysis | HIV- (n = 151) | HIV+ (n = 49) | Odds Ratio (95% IC) | p -value |
SVR, % (n) | 83.4 % (126) | 85.7 % (42) | 1.19 (0.5-3.1) | 0.7 |